Moreover, additional in vitro and in vivo studies on preclinical animal models will help to further investigate the role of SIRT1 and SIRT3 in the pathophysiology of SSc, and to unravel if the modulation of their expression and activity might provide new targeted therapeutic approaches for the treatment of this devastating disease. The gene discussed is SIRT3; the disease is systemic sclerosis.